Vandetanib is a quinazoline compound with the structure 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline, featuring additional methoxy and 4-bromo-2-fluorophenylamino groups at positions 6 and 4, respectively. It is used in the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Vandetanib functions as a tyrosine kinase inhibitor and antineoplastic agent. It is classified as an aromatic ether, secondary amine, quinazoline, piperidine, organobromine, and organofluorine compound.
